Search Results

You are looking at 1 - 10 of 64 items for :

  • 177Lu-DOTATATE x
  • Refine by Access: All content x
Clear All
Free access

Satya Das, Liping Du, Aimee Schad, Shikha Jain, Aaron Jessop, Chirayu Shah, David Eisner, Dana Cardin, Kristen Ciombor, Laura Goff, Marques Bradshaw, Dominique Delbeke, Martin Sandler, and Jordan Berlin

patients with NETs, its regulatory approvals occurred much more recently ( Otte et al. 1999 , Valkema et al. 2002 ). Lutetium-177 ( 177 Lu)-DOTATATE was approved by the European Medicines Agency (EMA) in 2017 and the Food and Drug Administration (FDA

Free access

Luohai Chen, Gopinath Gnanasegaran, Dalvinder Mandair, Christos Toumpanakis, Martyn Caplin, and Shaunak Navalkissoor

Introduction 177 Lutetium-DOTA 0 -Tyr 3 -octreotate ( 177 Lu-Dotatate) is a peptide receptor radionuclide therapy (PRRT) licensed for treatment in patients with advanced well-differentiated gastroenteropancreatic neuroendocrine tumours (NET

Free access

Tessa Brabander, Wouter A van der Zwan, Jaap J M Teunissen, Boen L R Kam, Wouter W de Herder, Richard A Feelders, Eric P Krenning, and Dik J Kwekkeboom

for PRRT are Yttrium-90 and Lutetium-177, linked to [DOTA 0 ,Tyr 3 ]octreotide ( 90 Y-DOTATOC) or [DOTA 0 ,Tyr 3 ]octreotate ( 177 Lu-DOTATATE), respectively. The objective response rate in patients with gastroenteropancreatic neuroendocrine tumours

Free access

Mintallah Haider, Satya Das, Taymeyah Al-Toubah, Eleonora Pelle, Ghassan El-Haddad, and Jonathan Strosberg

renal toxicity with 177 Lu-DOTATATE is negligible when prophylactic amino acids are used, even in patients with a glomerular filtration rate < 50mL/min ( Strosberg et al. 2018 b ). Of note, typical formulations of amino acids used for PRRT contain 25

Free access

G A Kaltsas, D Papadogias, P Makras, and A B Grossman

–30%) have been obtained in studies using 90 Y-DOTATOC ( Chinol et al. 2002 , Waldherr et al. 2002 , Bodei et al. 2003 , Valkema et al. 2005 ), and approximately 30% in those using 177 Lu- 177 Lu-DOTA-Tyr 3 -octreotate (DOTATATE) ( Krenning et

Free access

David Taïeb, Abhishek Jha, Giorgio Treglia, and Karel Pacak

(ileal in 75% of patients) ( Strosberg et al. 2017 ). The interim analysis was encouraging for 177 Lu-DOTATATE, with an objective response of 18 vs 3% compared to octreotide alone, with median progression-free survival (PFS) not yet reached in 177 Lu-DOTATATE

Free access

Tessa Brabander, Julie Nonnekens, and Johannes Hofland

radionuclide therapy (PRRT) ( Kwekkeboom et al. 2005 ). This was successfully implemented for [ 90 Y]Y-DOTA-[Tyr3]octreotide ( 90 Y-DOTATOC) and [ 177 Lu]Lu-DOTA-[Tyr3]octreotate ( 177 Lu-DOTATATE), with the latter radioligand now registered for therapy of

Free access

Jaap J M Teunissen, Dik J Kwekkeboom, R Valkema, and Eric P Krenning

) , different radiolabelled somatostatin analogues were evaluated for future clinical therapeutic use. Besides [ 111 In-DTPA 0 ]octreotide and 90 Y-DOTATOC, the β-emitting radionuclide 177 Lu coupled to DOTATATE ( 177 Lu-DOTATATE) was used. 177 Lu-DOTATATE

Open access

Tobias Hofving, Viktor Sandblom, Yvonne Arvidsson, Emman Shubbar, Gülay Altiparmak, John Swanpalmer, Bilal Almobarak, Anna-Karin Elf, Viktor Johanson, Erik Elias, Erik Kristiansson, Eva Forssell-Aronsson, and Ola Nilsson

-016-3382-9 ) 10.1007/s00259-016-3382-9 27160225 Bergsma H van Lom K Raaijmakers M Konijnenberg M Kam B Teunissen JJM de Herder WW Krenning EP Kwekkeboom DJ 2018 Persistent hematologic dysfunction after peptide receptor radionuclide therapy with (177)Lu-DOTATATE

Free access

Murali Kesavan, Piyush Grover, Wei-sen Lam, Phillip G Claringbold, and J Harvey Turner

dysfunction after peptide receptor radionuclide therapy with 177Lu-DOTATATE: incidence, course, and predicting factors in patients with gastroenteropancreatic neuroendocrine tumors . Journal of Nuclear Medicine 59 452 – 458 . (